290 related articles for article (PubMed ID: 24705981)
1. STAT3 inhibitors: finding a home in lymphoma and leukemia.
Munoz J; Dhillon N; Janku F; Watowich SS; Hong DS
Oncologist; 2014 May; 19(5):536-44. PubMed ID: 24705981
[TBL] [Abstract][Full Text] [Related]
2. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
3. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.
Kim BH; Yin CH; Guo Q; Bach EA; Lee H; Sandoval C; Jayabose S; Ulaczyk-Lesanko A; Hall DG; Baeg GH
Mol Cancer Ther; 2008 Sep; 7(9):2672-80. PubMed ID: 18790749
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
7. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?
Sriram K; Benkovic SA; Hebert MA; Miller DB; O'Callaghan JP
J Biol Chem; 2004 May; 279(19):19936-47. PubMed ID: 14996842
[TBL] [Abstract][Full Text] [Related]
8. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
Sansone P; Bromberg J
J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.
Aparicio-Siegmund S; Sommer J; Monhasery N; Schwanbeck R; Keil E; Finkenstädt D; Pfeffer K; Rose-John S; Scheller J; Garbers C
Oncotarget; 2014 Apr; 5(8):2131-48. PubMed ID: 24742922
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
11. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia.
Huang L; Liu D; Wang N; Ling S; Tang Y; Wu J; Hao L; Luo H; Hu X; Sheng L; Zhu L; Wang D; Luo Y; Shang Z; Xiao M; Mao X; Zhou K; Cao L; Dong L; Zheng X; Sui P; He J; Mo S; Yan J; Ao Q; Qiu L; Zhou H; Liu Q; Zhang H; Li J; Jin J; Fu L; Zhao W; Chen J; Du X; Qing G; Liu H; Liu X; Huang G; Ma D; Zhou J; Wang QF
Cell Res; 2018 Feb; 28(2):172-186. PubMed ID: 29148541
[TBL] [Abstract][Full Text] [Related]
13. HiJAKing the epigenome in leukemia and lymphoma.
Drennan AC; Rui L
Leuk Lymphoma; 2017 Nov; 58(11):2540-2547. PubMed ID: 28402164
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia.
Teramo A; Gattazzo C; Passeri F; Lico A; Tasca G; Cabrelle A; Martini V; Frezzato F; Trimarco V; Ave E; Boscaro E; Piazza F; Facco M; Trentin L; Semenzato G; Zambello R
Blood; 2013 May; 121(19):3843-54, S1. PubMed ID: 23515927
[TBL] [Abstract][Full Text] [Related]
15. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
16. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.
Kim BH; Min YS; Choi JS; Baeg GH; Kim YS; Shin JW; Kim TY; Ye SK
Exp Mol Med; 2011 May; 43(5):313-21. PubMed ID: 21499010
[TBL] [Abstract][Full Text] [Related]
17. Effects of thrombopoietin, interleukin-3 and the kinase inhibitor K-252a on growth and polyploidization of the megakaryocytic cell line M-07e.
Quentmeier H; Zaborski M; Drexler HG
Leukemia; 1998 Oct; 12(10):1603-11. PubMed ID: 9766506
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
19. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells.
Zhang HY; Zhang Q; Zhang X; Yu C; Huo X; Cheng E; Wang DH; Spechler SJ; Souza RF
Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G454-60. PubMed ID: 21148399
[TBL] [Abstract][Full Text] [Related]
20. Regulating RISK: a role for JAK-STAT signaling in postconditioning?
Goodman MD; Koch SE; Fuller-Bicer GA; Butler KL
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1649-56. PubMed ID: 18708442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
